A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Summary

This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Moderately to Severely Active Crohns Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

16 to 80 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Hoffmann-La Roche

Last updated on ClinicalTrials.gov

September 28, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites